Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RMC-9805 + RMC-6236 + gemcitabine + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- REVOLUTION Medicines
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
This is an investigational **combination therapy** consisting of two *novel small molecule inhibitors* (RMC-9805 and RMC-6236, both RAS(ON) inhibitors targeting KRAS-mutant solid tumors) with the approved chemotherapies **gemcitabine** (a nucleoside analog targeting DNA synthesis) and **nab-paclitaxel** (an albumin-bound nanoparticle formulation of paclitaxel that disrupts microtubules). RMC-9805 is a selective oral inhibitor targeting **KRAS G12D(ON)**, and RMC-6236 is an oral small molecule inhibitor targeting a broader range of RAS(ON) active forms. This regimen aims to synergistically inhibit tumor growth through direct RAS pathway blockade and cytotoxic effects of chemotherapy. The primary indication is for advanced gastrointestinal malignancies, especially **KRAS G12D-mutant solid tumors** and pancreatic or colorectal cancers[1][3][5][7][9].
- Other names
- Abraxane (nab-paclitaxel)Gemzar (gemcitabine)
02
Targets
DNA polymerase familyKRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on RMC-9805 + RMC-6236 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RMC-9805 + RMC-6236 + gemcitabine + nab-paclitaxel.